PDS Biotechnology Corp

For the period ended Mar 31, 2024. Filed May 15, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 15, 2024

PDSB$1.03-4.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

Statements of Cash Flows

	Three Months Ended March 31,
	2024	2023
Cash flows from operating activities:
Net loss	$(10,603,477)	$(9,659,918)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,630,011	2,080,319
Amortization of debt discount	270,236	121,997
Depreciation expense	4,735	3,155
Operating lease expense	–	60,257
Finance lease depreciation expense	9,670	10,957
Changes in assets and liabilities:
Prepaid expenses and other assets	443,210	(113,758)
Accounts payable	(981,993)	852,774
Accrued expenses	(710,581)	(6,455,317)
Operating lease liabilities	–	(89,102)
Net cash used in operating activities	(9,938,189)	(13,188,636)
Cash flows from financing activities:
Proceeds from exercise of stock options	531,091	–
Payments of finance lease obligations	(13,475)	(20,667)
Proceeds from issuance of common stock, net of issuance costs	19,494,473	4,588,522
Net cash provided by financing activities	20,012,089	4,567,855
Net increase in cash and cash equivalents	10,073,900	(8,620,781)
Cash and cash equivalents at beginning of period	56,560,517	73,820,160
Cash and cash equivalents at the end of period	$66,634,417	$65,199,379
Supplemental information of cash and non-cash transactions:
Cash paid for interest	$1,174,745	$966,845

Index

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.